Post by PharmaShots

Eli Lilly and Company presents the P-III (TRIUMPH-1 and TRANSCEND-T2D-1) trial results at ADA 2026, showing Retatrutide delivered improvements across obesity, type 2 diabetes, and knee osteoarthritis pain and obstructive sleep apnea  Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #elililly #retatrutide #kneeosteoarthritis #obstructivesleepapnea #obesity #transcendt2d1 #triumph1 #clinicaltrial #ada2026 https://lnkd.in/gCBhRFAq